A machine learning approach to identify clinical trials involving nanodrugs and nanodevices from ClinicalTrials.gov.
BACKGROUND:Clinical Trials (CTs) are essential for bridging the gap between experimental research on new drugs and their clinical application. Just like CTs for traditional drugs and biologics have helped accelerate the translation of biomedical findings into medical practice, CTs for nanodrugs and...
Main Authors: | Diana de la Iglesia, Miguel García-Remesal, Alberto Anguita, Miguel Muñoz-Mármol, Casimir Kulikowski, Víctor Maojo |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0110331 |
Similar Items
-
Problematic trial detection in ClinicalTrials.gov
by: Chris Hartgerink, et al.
Published: (2015-12-01) -
Registration of phase 3 crossover trials on ClinicalTrials.gov
by: Lijuan Zeng, et al.
Published: (2020-07-01) -
Obstacles to the reuse of study metadata in ClinicalTrials.gov
by: Laura Miron, et al.
Published: (2020-12-01) -
Some data quality issues at ClinicalTrials.gov
by: Neha Chaturvedi, et al.
Published: (2019-06-01) -
Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov
by: Yan-Bo Wang, et al.
Published: (2020-01-01)